☰

Mark Chao, MD, PhD - Publications

Affiliations: 
2008-2017 Stanford University, Palo Alto, CA 
 2016- Forty Seven, Inc. 
Tree Info Similar researchers PubMed Report error

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, Volkmer JP, Weissman IL, Majeti R. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Frontiers in Oncology. 9: 1380. PMID 32038992 DOI: 10.3389/fonc.2019.01380  0.92
2019 Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, ... Chao MP, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802018. PMID 30811285 DOI: 10.1200/JCO.18.02018  0.92
2019 Chao MP, Majeti R. Induced pluripotent stem cell modeling of malignant hematopoiesis. Experimental Hematology. PMID 30659850 DOI: 10.1016/j.exphem.2019.01.002  0.92
2018 Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, ... ... Chao MP, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine. 379: 1711-1721. PMID 30380386 DOI: 10.1056/NEJMoa1807315  0.92
2016 Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, Xavy S, Shen J, Haag D, Chanda S, Sinha R, Morganti RM, Nishimura T, Ameen M, Wu H, et al. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell. PMID 28089908 DOI: 10.1016/j.stem.2016.11.018  0.92
2016 Weiskopf K, Schnorr PJ, Pang WW, Chao MP, Chhabra A, Seita J, Feng M, Weissman IL. Myeloid Cell Origins, Differentiation, and Clinical Implications. Microbiology Spectrum. 4. PMID 27763252 DOI: 10.1128/microbiolspec.MCHD-0031-2016  0.88
2015 Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. Plos One. 10: e0137345. PMID 26390038 DOI: 10.1371/journal.pone.0137345  0.92
2015 Chao MP, Hong J, Kunder C, Lester L, Schrier SL, Majeti R. Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab. American Journal of Hematology. 90: 78-81. PMID 24942207 DOI: 10.1002/ajh.23791  0.88
2012 Han MH, Lundgren DH, Jaiswal S, Chao M, Graham KL, Garris CS, Axtell RC, Ho PP, Lock CB, Woodard JI, Brownell SE, Zoudilova M, Hunt JF, Baranzini SE, Butcher EC, et al. Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. The Journal of Experimental Medicine. 209: 1325-34. PMID 22734047 DOI: 10.1084/jem.20101974  0.88
2012 Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 109: 6662-7. PMID 22451913 DOI: 10.1073/pnas.1121623109  0.88
2012 Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Current Opinion in Immunology. 24: 225-32. PMID 22310103 DOI: 10.1016/j.coi.2012.01.010  0.88
2012 Chao MP, Majeti R, Weissman IL. Programmed cell removal: a new obstacle in the road to developing cancer. Nature Reviews. Cancer. 12: 58-67. PMID 22158022 DOI: 10.1038/nrc3171  0.88
2011 Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 118: 4890-901. PMID 21828138 DOI: 10.1182/blood-2011-02-338020  0.88
2011 Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proceedings of the National Academy of Sciences of the United States of America. 108: 5009-14. PMID 21383193 DOI: 10.1073/pnas.1100551108  0.88
2011 Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 117: 2423-32. PMID 21193697 DOI: 10.1182/blood-2010-08-301945  0.88
2011 Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Research. 71: 1374-84. PMID 21177380 DOI: 10.1158/0008-5472.CAN-10-2238  0.88
2010 Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Science Translational Medicine. 2: 63ra94. PMID 21178137 DOI: 10.1126/scitranslmed.3001375  0.88
2010 Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142: 699-713. PMID 20813259 DOI: 10.1016/j.cell.2010.07.044  0.88
2010 Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends in Immunology. 31: 212-9. PMID 20452821 DOI: 10.1016/j.it.2010.04.001  0.88
2009 Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J, Chang HY, van de Rijn M, Shortliffe L, Weissman IL. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America. 106: 14016-21. PMID 19666525 DOI: 10.1073/pnas.0906549106  0.88
2009 Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 138: 286-99. PMID 19632179 DOI: 10.1016/j.cell.2009.05.045  0.88
2009 Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 138: 271-85. PMID 19632178 DOI: 10.1016/j.cell.2009.05.046  0.88
2006 Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proceedings of the National Academy of Sciences of the United States of America. 103: 6224-9. PMID 16603627 DOI: 10.1073/pnas.0601462103  0.88
Show low-probability matches.